GoodRx Holdings, Inc.
$1.42B- Market cap
- $1.18B
- Debt
- +$500.00M
- Cash
- −$261.82M
Capital structure 70% equity / 30% debt · EV / Revenue 1.78x · EV / EBITDA 7.54x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 ·
Decision snapshot: GDRX stock price at premium vs CACI $3.48 current versus $2.32 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CACI's multiple
Implied fair value · at GDRX's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Expensive
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GDRX FY 2025 (ended Dec 31, 2025) · CACI FY 2026 (ended Jun 30, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 70% equity / 30% debt · EV / Revenue 1.78x · EV / EBITDA 7.54x
Capital structure 74% equity / 26% debt · EV / Revenue 1.94x · EV / EBITDA 17.07x
CACI carries the larger enterprise value at $18.54B against $1.42B; GDRX trades on the lower EV / Revenue multiple (1.78x vs 1.94x); GDRX on the lower EV / EBITDA (7.54x vs 17.07x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GoodRx Holdings, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
CACI INTERNATIONAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.81x
1.11x
Net debt / EBITDA
Leverage against operating earnings
1.26x
4.38x
Cash and equivalents
Liquid reserves on the balance sheet
$261.82M
$191.76M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Evolent Health, Inc.
GDRX vs EVH
CVS HEALTH Corp
GDRX vs CVS
Doximity, Inc.
GDRX vs DOCS
Criteo S.A.
GDRX vs CRTO
Science Applications International Corp
GDRX vs SAIC
KBR, INC.
GDRX vs KBR
Booz Allen Hamilton Holding Corp
GDRX vs BAH
Leidos Holdings, Inc.
GDRX vs LDOS
JACOBS SOLUTIONS INC.
GDRX vs J
$500.00M
$4.95B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.